Adams Diversified Equity Fund (ADX) Competitors

iShares Biotechnology ETF (NASDAQ:IBB) and Adams Diversified Equity Fund (NYSE:ADX) are both mid-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, community ranking, analyst recommendations, risk and earnings.

Do institutionals and insiders hold more shares of IBB or ADX?

62.5% of iShares Biotechnology ETF shares are owned by institutional investors. Comparatively, 28.4% of Adams Diversified Equity Fund shares are owned by institutional investors. 0.1% of Adams Diversified Equity Fund shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Is IBB or ADX a better dividend stock?

iShares Biotechnology ETF pays an annual dividend of $0.40 per share and has a dividend yield of 0.3%. Adams Diversified Equity Fund pays an annual dividend of $1.30 per share and has a dividend yield of 6.4%.

Does the media favor IBB or ADX?

In the previous week, Adams Diversified Equity Fund had 1 more articles in the media than iShares Biotechnology ETF. MarketBeat recorded 4 mentions for Adams Diversified Equity Fund and 3 mentions for iShares Biotechnology ETF. Adams Diversified Equity Fund's average media sentiment score of 0.80 beat iShares Biotechnology ETF's score of 0.18 indicating that iShares Biotechnology ETF is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iShares Biotechnology ETF	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adams Diversified Equity Fund	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable valuation and earnings, IBB or ADX?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iShares Biotechnology ETF	N/A	N/A	N/A	N/A	N/A
Adams Diversified Equity Fund	N/A	N/A	N/A	N/A	N/A

Do analysts rate IBB or ADX?

Given Adams Diversified Equity Fund's higher possible upside, equities research analysts clearly believe iShares Biotechnology ETF is more favorable than Adams Diversified Equity Fund.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iShares Biotechnology ETF	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56
Adams Diversified Equity Fund	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Is IBB or ADX more profitable?

Company	Net Margins	Return on Equity	Return on Assets
iShares Biotechnology ETF	N/A	N/A	N/A
Adams Diversified Equity Fund	N/A	N/A	N/A

Which has more risk and volatility, IBB or ADX?

iShares Biotechnology ETF has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Adams Diversified Equity Fund has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.

Does the MarketBeat Community favor IBB or ADX?

iShares Biotechnology ETF received 13 more outperform votes than Adams Diversified Equity Fund when rated by MarketBeat users. Likewise, 67.09% of users gave iShares Biotechnology ETF an outperform vote while only 53.09% of users gave Adams Diversified Equity Fund an outperform vote.

Company	Underperform	Outperform
iShares Biotechnology ETF	Outperform Votes 159 67.09%	Underperform Votes 78 32.91%
Adams Diversified Equity Fund	Outperform Votes 146 53.09%	Underperform Votes 129 46.91%

Summary

iShares Biotechnology ETF beats Adams Diversified Equity Fund on 6 of the 10 factors compared between the two stocks.